Selecta Biosciences announced Thursday that it will stop investment in most of its pipeline assets except for a treatment for chronic refractory gout licensed to Swedish pharma Sobi and a gene therapy it’s developing with Astellas.
The company plans to submit a BLA for SEL-212 in the first half of…
Click here to view original post
